N. Chalasani, The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology, American Association for the Study of Liver Diseases, and American College of Gastroenterology, pp.1592-1609, 2012.
DOI : 10.1053/j.gastro.2012.04.001

P. Angulo, Nonalcoholic Fatty Liver Disease, New England Journal of Medicine, vol.346, issue.16, pp.1221-1231, 2002.
DOI : 10.1056/NEJMra011775

R. J. Wong, Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States, Gastroenterology, vol.148, issue.3, pp.547-555, 2015.
DOI : 10.1053/j.gastro.2014.11.039

M. R. Charlton, Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States, Gastroenterology, vol.141, issue.4, pp.1249-1253, 2011.
DOI : 10.1053/j.gastro.2011.06.061

G. Baffy, E. M. Brunt, and S. H. Caldwell, Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace, Journal of Hepatology, vol.56, issue.6, pp.1384-1391, 2012.
DOI : 10.1016/j.jhep.2011.10.027

G. Vernon, A. Baranova, and Z. M. Younossi, Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults, Alimentary Pharmacology & Therapeutics, vol.11, issue.6 Pt 2, pp.274-285, 2011.
DOI : 10.1111/j.1365-2036.2011.04724.x

C. D. Williams, Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study, Gastroenterology, vol.140, issue.1, pp.124-131, 2011.
DOI : 10.1053/j.gastro.2010.09.038

L. A. Adams, The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study, Gastroenterology, vol.129, issue.1, pp.113-121, 2005.
DOI : 10.1053/j.gastro.2005.04.014

M. Ekstedt, Long-term follow-up of patients with NAFLD and elevated liver enzymes, Hepatology, vol.128, issue.4, pp.865-873, 2006.
DOI : 10.1002/hep.21327

P. Angulo, Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease, Gastroenterology, vol.149, issue.2, pp.389-397, 2015.
DOI : 10.1053/j.gastro.2015.04.043

M. Ekstedt, Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up, Hepatology, vol.57, issue.5, pp.1547-1554, 2015.
DOI : 10.1002/hep.27368

J. F. Cadranel, P. Rufat, and F. Degos, Practices of Liver Biopsy in France: Results of a Prospective Nationwide Survey, Hepatology, vol.34, issue.3, pp.477-481, 2000.
DOI : 10.1053/jhep.2000.16602

D. C. Rockey, Liver biopsy, Hepatology, vol.33, issue.Suppl 4, pp.1017-1044, 2009.
DOI : 10.1002/hep.22742

P. Bedossa, D. Dargère, and V. Paradis, Sampling variability of liver fibrosis in chronic hepatitis C, Hepatology, vol.36, issue.6, pp.1449-1457, 2003.
DOI : 10.1016/j.hep.2003.09.022

A. L. Fracanzani, Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes, Hepatology, vol.29, issue.3, pp.792-798, 2008.
DOI : 10.1002/hep.22429

V. De-lédinghen, Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained elevated transaminases. A prospective multicenter study, Journal of Hepatology, vol.45, issue.4, pp.592-599, 2006.
DOI : 10.1016/j.jhep.2006.05.008

P. Calès, Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease, Liver International, vol.50, issue.9, pp.1346-1354, 2010.
DOI : 10.1111/j.1478-3231.2010.02314.x

P. Angulo, Simple Noninvasive Systems Predict Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease, Gastroenterology, vol.145, issue.4, pp.782-789, 2013.
DOI : 10.1053/j.gastro.2013.06.057

T. Poynard, The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis, Comparative Hepatology, vol.4, issue.1, p.10, 2005.
DOI : 10.1186/1476-5926-4-10

A. E. Feldstein, Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, The Journal of Lipid Research, vol.51, issue.10, pp.3046-3054, 2010.
DOI : 10.1194/jlr.M007096

T. Poynard, Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease, BMC Gastroenterology, vol.128, issue.1, p.34, 2006.
DOI : 10.1053/j.gastro.2005.02.056

J. Boursier, Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease, Journal of Hepatology, vol.65, issue.3, 2016.
DOI : 10.1016/j.jhep.2016.04.023

G. Sebastiani, Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis, PLOS ONE, vol.28, issue.Suppl 2, p.128774, 2015.
DOI : 10.1371/journal.pone.0128774.t004

J. Chen, Y. Zhu, Q. Zheng, and J. Jiang, Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis: A meta-analysis, Hepatology Research, vol.14, issue.7109
DOI : 10.1111/hepr.12197

R. Kwok, Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease - the role of transient elastography and plasma cytokeratin-18 fragments, Alimentary Pharmacology & Therapeutics, vol.6, issue.3, pp.254-269, 2014.
DOI : 10.1111/apt.12569

R. Anty, A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients, Alimentary Pharmacology & Therapeutics, vol.17, issue.11-12, pp.1315-1322, 2010.
DOI : 10.1111/j.1365-2036.2010.04480.x

URL : https://hal.archives-ouvertes.fr/hal-00583896

Z. M. Younossi, A Biomarker Panel for Non-alcoholic Steatohepatitis (NASH) and NASH-Related Fibrosis, Obesity Surgery, vol.37, issue.1, pp.431-439, 2011.
DOI : 10.1007/s11695-010-0204-1

N. Rifai, M. A. Gillette, and S. A. Carr, Protein biomarker discovery and validation: the long and uncertain path to clinical utility, Nature Biotechnology, vol.33, issue.8, pp.971-983, 2006.
DOI : 10.1038/nbt1235

A. G. Paulovich, J. R. Whiteaker, A. N. Hoofnagle, and P. Wang, The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline, PROTEOMICS - CLINICAL APPLICATIONS, vol.44, issue.10-11, pp.1386-1402, 2008.
DOI : 10.1002/prca.200780174

R. Hüttenhain, J. Malmström, P. Picotti, and R. Aebersold, Perspectives of targeted mass spectrometry for protein biomarker verification, Curr. Opin. Chem

T. Sajic, Y. Liu, and R. Aebersold, Using data-independent, high-resolution mass spectrometry in protein biomarker research: Perspectives and clinical applications, PROTEOMICS - Clinical Applications, vol.19, issue.3-4, 2014.
DOI : 10.1002/prca.201400117

V. Brun, Isotope-labeled Protein Standards: Toward Absolute Quantitative Proteomics, Molecular & Cellular Proteomics, vol.6, issue.12, pp.2139-2149, 2007.
DOI : 10.1074/mcp.M700163-MCP200

C. Huillet, Accurate quantification of cardiovascular biomarkers in serum using Protein Standard Absolute Quantification (PSAQ TM ) and selected reaction monitoring, Mol. Cell. Proteomics MCP, vol.11, issue.M111, p.8235, 2012.

G. Marchesini, Association of nonalcoholic fatty liver disease with insulin resistance, The American Journal of Medicine, vol.107, issue.5, pp.450-455, 1999.
DOI : 10.1016/S0002-9343(99)00271-5

E. Bugianesi, A. J. Mccullough, and G. Marchesini, Insulin resistance: A metabolic pathway to chronic liver disease, Hepatology, vol.96, issue.5, pp.987-1000, 2005.
DOI : 10.1002/hep.20920

E. Buzzetti, M. Pinzani, and E. A. Tsochatzis, The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD), Metabolism, vol.65, issue.8, pp.1038-1048, 2016.
DOI : 10.1016/j.metabol.2015.12.012

N. Chalasani, The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology, American Association for the Study of Liver Diseases, and American College of Gastroenterology, pp.1592-1609, 2012.
DOI : 10.1053/j.gastro.2012.04.001

G. Vernon, A. Baranova, and Z. M. Younossi, Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults, Alimentary Pharmacology & Therapeutics, vol.11, issue.6 Pt 2, pp.274-285, 2011.
DOI : 10.1111/j.1365-2036.2011.04724.x

C. D. Williams, Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study, Gastroenterology, vol.140, issue.1, pp.124-131, 2011.
DOI : 10.1053/j.gastro.2010.09.038

M. Ekstedt, Long-term follow-up of patients with NAFLD and elevated liver enzymes, Hepatology, vol.128, issue.4, pp.865-873, 2006.
DOI : 10.1002/hep.21327

L. A. Adams, The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study, Gastroenterology, vol.129, issue.1, pp.113-121, 2005.
DOI : 10.1053/j.gastro.2005.04.014

J. F. Cadranel, P. Rufat, and F. Degos, Practices of Liver Biopsy in France: Results of a Prospective Nationwide Survey, Hepatology, vol.34, issue.3, pp.477-481, 2000.
DOI : 10.1053/jhep.2000.16602

D. C. Rockey, Liver biopsy, Hepatology, vol.33, issue.Suppl 4, pp.1017-1044, 2009.
DOI : 10.1002/hep.22742

P. Bedossa, D. Dargère, and V. Paradis, Sampling variability of liver fibrosis in chronic hepatitis C, Hepatology, vol.36, issue.6, pp.1449-1457, 2003.
DOI : 10.1016/j.hep.2003.09.022

A. E. Feldstein and G. J. Gores, Apoptosis in alcoholic and nonalcoholic steatohepatitis, Frontiers in Bioscience, vol.10, issue.1-3, pp.3093-3099, 2005.
DOI : 10.2741/1765

A. L. Fracanzani, Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes, Hepatology, vol.29, issue.3, pp.792-798, 2008.
DOI : 10.1002/hep.22429

P. Calès, Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease, Liver International, vol.50, issue.9, pp.1346-1354, 2010.
DOI : 10.1111/j.1478-3231.2010.02314.x

T. Poynard, Performance of Biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in Patients with Severe Obesity: Meta Analysis of Individual Patient Data, PLoS ONE, vol.49, issue.3, p.30325, 2012.
DOI : 10.1371/journal.pone.0030325.s005

K. G. Alberti, Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity, Circulation, vol.120, issue.16, pp.1640-1645, 2009.
DOI : 10.1161/CIRCULATIONAHA.109.192644

D. E. Kleiner, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, vol.38, issue.6, pp.1313-1321, 2005.
DOI : 10.1002/hep.20701

P. Bedossa, Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients, Hepatology, vol.100, issue.5, pp.1751-1759, 2012.
DOI : 10.1002/hep.25889

P. Bedossa, . Flip-pathology, and . Consortium, Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease, Hepatology, vol.7, issue.2, pp.565-575, 2014.
DOI : 10.1002/hep.27173

N. Bhala, R. I. Jouness, and E. Bugianesi, Epidemiology and Natural History of Patients with NAFLD, Current Pharmaceutical Design, vol.19, issue.29, pp.5169-5176, 2013.
DOI : 10.2174/13816128113199990336

A. E. Feldstein, Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study, Hepatology, vol.48, issue.4
DOI : 10.1002/hep.23050

J. B. Saunders, O. G. Aasland, T. F. Babor, J. R. De-la-fuente, and M. Grant, Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II, Addiction, vol.i, issue.6, pp.791-804, 1993.
DOI : 10.1111/j.1360-0443.1993.tb02093.x

D. A. Fiellin, M. C. Reid, and P. G. O-'connor, Screening for Alcohol Problems in Primary Care, Archives of Internal Medicine, vol.160, issue.13, pp.1977-1989, 2000.
DOI : 10.1001/archinte.160.13.1977

R. Vuppalanchi, Relationship Between Changes in Serum Levels of Keratin 18 and Changes in Liver Histology in Children and Adults With Nonalcoholic Fatty Liver Disease, Clinical Gastroenterology and Hepatology, vol.12, issue.12
DOI : 10.1016/j.cgh.2014.05.010

W. Chan, P. Sthaneshwar, N. R. Nik-mustapha, and S. Mahadeva, Limited Utility of Plasma M30 in Discriminating Non-Alcoholic Steatohepatitis from Steatosis ??? A Comparison with Routine Biochemical Markers, PLoS ONE, vol.24, issue.9, p.105903, 2014.
DOI : 10.1371/journal.pone.0105903.s009

E. M. Brunt, Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings, Hepatology, vol.44, issue.3
DOI : 10.1002/hep.24127

P. Bedossa, Current histological classification of NAFLD: strength and limitations, Hepatology International, vol.100, issue.7, pp.765-770, 2013.
DOI : 10.1007/s12072-013-9446-z

I. L. Nalbantoglu and E. M. Brunt, Role of liver biopsy in nonalcoholic fatty liver disease, World J. Gastroenterol, vol.20, pp.9026-9037, 2014.

M. Ekstedt, Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up, Hepatology, vol.57, issue.5, pp.1547-1554, 2015.
DOI : 10.1002/hep.27368

P. Angulo, Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease, Gastroenterology, vol.149, issue.2, pp.389-397, 2015.
DOI : 10.1053/j.gastro.2015.04.043

M. Ekstedt, L. E. Franzén, U. L. Mathiesen, and S. Kechagias, Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression, Scandinavian Journal of Gastroenterology, vol.44, issue.2, pp.108-115, 2012.
DOI : 10.1053/j.gastro.2005.03.084

B. A. Neuschwander-tetri, Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial, The Lancet, vol.385, issue.9972, pp.956-965, 2015.
DOI : 10.1016/S0140-6736(14)61933-4

K. Promrat, Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis, Hepatology, vol.39, issue.Suppl 1, pp.121-129, 2010.
DOI : 10.1002/hep.23276

A. J. Sanyal, Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis, New England Journal of Medicine, vol.362, issue.18, pp.1675-1685, 2010.
DOI : 10.1056/NEJMoa0907929

L. A. Adams and V. Ratziu, Non-alcoholic fatty liver ??? Perhaps not so benign, Journal of Hepatology, vol.62, issue.5, pp.1002-1004, 2015.
DOI : 10.1016/j.jhep.2015.02.005

S. Singh, Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies, Clinical Gastroenterology and Hepatology, vol.13, issue.4
DOI : 10.1016/j.cgh.2014.04.014

S. Mcpherson, Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management, Journal of Hepatology, vol.62, issue.5, pp.1148-1155, 2015.
DOI : 10.1016/j.jhep.2014.11.034

C. K. Argo, P. G. Northup, A. M. Osaimi, and S. H. Caldwell, Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis, Journal of Hepatology, vol.51, issue.2, pp.371-379, 2009.
DOI : 10.1016/j.jhep.2009.03.019

S. A. Polyzos, Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index, Ann. Hepatol, vol.12, pp.749-757, 2013.

M. Grigorescu, A novel pathophysiological-based panel of biomarkers for the diagnosis of nonalcoholic steatohepatitis, J. Physiol. Pharmacol. Off. J. Pol. Physiol. Soc, vol.63, pp.347-353, 2012.

S. S. Baker, R. D. Baker, W. Liu, N. J. Nowak, and L. Zhu, Role of Alcohol Metabolism in Non-Alcoholic Steatohepatitis, PLoS ONE, vol.5, issue.3, p.9570, 2010.
DOI : 10.1371/journal.pone.0009570.t005

Z. M. Younossi, Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality, Hepatology, vol.36, issue.Suppl 1
DOI : 10.1002/hep.24268

A. J. Sanyal, Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop, Hepatology, vol.105, issue.4, pp.1392-1405, 2015.
DOI : 10.1002/hep.27678

A. J. Sanyal, B. A. Neuschwander-tetri, and J. Tonascia, End Points Must Be Clinically Meaningful for Drug Development in Nonalcoholic Fatty Liver Disease, Gastroenterology, vol.150, issue.1, pp.11-13, 2016.
DOI : 10.1053/j.gastro.2015.11.017

S. M. Francque, D. Van-der-graaff, and W. J. Kwanten, Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications, Journal of Hepatology, vol.65, issue.2, pp.425-443, 2016.
DOI : 10.1016/j.jhep.2016.04.005

S. Romeo, Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease, Nature Genetics, vol.164, issue.12, pp.1461-1465, 2008.
DOI : 10.1038/ng1984

Y. Liu, TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease, Nature Communications, vol.81, p.4309, 2014.
DOI : 10.1038/ncomms5309

H. W. Lee, Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease, PLOS ONE, vol.7, issue.6, p.157358, 2016.
DOI : 10.1371/journal.pone.0157358.s001